FDA approves Novartis' Lutathera for GEP-NETs

FDA approved Lutathera (177-Lu-Dotatate) from Novartis AG (NYSE:NVS; SIX:NOVN) to treat somatostatin receptor-positive gastroenteropancreatic

Read the full 148 word article

User Sign In